Compositions and methods for metabolic control of a biofermentation process with synthetic metabolic valves
The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.
1. A multi-stage fermentation bioprocess for producing a product from a genetically modified microorganism, comprising:
providing a genetically modified microorganism having a production pathway for producing a product that is: an amino acid, acetate, acetoin, acetone, acrylic, malate, fatty acid ethyl esters, isoprenoids, glycerol, ethylene glycol, ethylene, propylene, butylene, isobutylene, ethyl acetate, vinyl acetate, 1,4-butanediol, 2,3-butanediol, butanol, isobutanol, sec-butanol, butyrate, isobutyrate, 2-OH-isobutyrate, 3-OH-butyrate, ethanol, isopropanol, D-lactate, L-lactate, pyruvate, itaconate, levulinate, glucarate, glutarate, caprolactam, adipic acid, propanol, isopropanol, fused alcohols, 1,2-propanediol, 1,3-propanediol, formate, fumaric acid, propionic acid, succinic acid, valeric acid, maleic acid, or poly-hydroxybutyrate;
growing the identified genetically modified microorganism in a media in a growth phase, the genetically modified microorganism comprising:
i. a production pathway comprising at least one production enzyme for biosynthesis of the product; and
ii. one or more synthetic metabolic valves for reducing or eliminating flux through multiple metabolic pathways within the genetically modified microorganism when the synthetic metabolic valves are induced, the one or more synthetic metabolic valves comprising:
a) at least one silencing synthetic metabolic valve that silences gene expression of a gene selected from: fabI, gltA, lpd, zwf, and udhA, or
b) at least one proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme selected from: fabI, gltA, lpd, zwf, and udhA;
transitioning to a productive stationary phase, the transition comprising:
depletion of a limiting nutrient;
inducing the one or more synthetic metabolic valves;
activation of the production pathway; and
producing the product.
2. The multi-stage fermentation bioprocess of claim 1 , wherein the microorganism comprises a silencing synthetic metabolic valve and a proteolytic synthetic metabolic valve, and wherein the activation of the silencing synthetic metabolic valve produces a product that enhances the function of the proteolytic synthetic metabolic valve.
3. The multi-stage fermentation bioprocess of claim 1 , wherein the microorganism comprises a chromosomal a deletion or disruption of a cas3 or sspB gene.
4. The multi-stage fermentation bioprocess of claim 1 , wherein the rate of production of said product during the productive stationary phase is reduced less in response to a change of an environmental condition as compared to a cell lacking the synthetic metabolic valves.
5. The multi-stage fermentation bioprocess of claim 1 , wherein the silencing synthetic metabolic valve silences gene expression of a gene selected from: fabI, gltA, lpd, zwf, and udhA and an additional gene.
6. The multi-stage fermentation bioprocess of claim 1 , wherein the proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme selected from: fabI, gltA, lpd, zwf, and udhA and an additional enzyme.
7. The multi-stage fermentation bioprocess of claim 1 , wherein at least one silencing synthetic metabolic valve is characterized by CRISPR interference of gene expression of a gene that is a fabI, gltA, lpd, zwf, or udhA gene and expression of a CASCADE plasmid comprising an array of guide RNA genes.
8. The multi-stage fermentation bioprocess of claim 1 , wherein at least one proteolytic synthetic metabolic valve is characterized by expression of the proteolytic enzyme operably linked to a C-terminal DAS4 peptide tag and controlled proteolysis of a fabI, gltA, ldp, zwf, or udhA enzyme by the synthetic metabolic valve is selective for the tag by clpXP protease upon induction of sspB chaperone protein.
9. The multi-stage fermentation bioprocess of claim 1 , wherein the microorganism has reduced level or activity of at least one metabolic enzyme prior to synthetic metabolic valve induction.
10. A multi-stage fermentation bioprocess for producing a product from a genetically modified E. coli , comprising:
providing a genetically modified E. coli having a production pathway for producing a product that is: an amino acid, acetate, acetoin, acetone, acrylic, malate, fatty acid ethyl esters, isoprenoids, glycerol, ethylene glycol, ethylene, propylene, butylene, isobutylene, ethyl acetate, vinyl acetate, 1,4-butanediol, 2,3-butanediol, butanol, isobutanol, sec-butanol, butyrate, isobutyrate, 2-OH-isobutyrate, 3-OH-butyrate, ethanol, isopropanol, D-lactate, L-lactate, pyruvate, itaconate, levulinate, glucarate, glutarate, caprolactam, adipic acid, propanol, isopropanol, fused alcohols, 1,2-propanediol, 1,3-propanediol, formate, fumaric acid, propionic acid, succinic acid, valeric acid, maleic acid, or poly-hydroxybutyrate;
growing the identified genetically modified E. coli in a media in a growth phase, the genetically modified E. coli comprising:
i. a production pathway comprising at least one production enzyme for biosynthesis of the product; and
ii. one or more synthetic metabolic valves for reducing or eliminating flux through multiple metabolic pathways within the genetically modified E. coli when the synthetic metabolic valves are induced, the one or more synthetic metabolic valves comprising:
a) at least one silencing synthetic metabolic valve that silences gene expression of a gene, or
b) at least one proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme;
transitioning to a productive stationary phase, the transition comprising:
depletion of a limiting nutrient;
inducing the one or more synthetic metabolic valves; and
activation of the production pathway; and
producing the product.
11. The multi-stage fermentation bioprocess of claim 10 , wherein the silencing synthetic metabolic valve that silences gene expression of a gene is a gene selected from the group: fabI, gltA, ldp, zwf, or udhA.
12. The multi-stage fermentation bioprocess of claim 10 , wherein the silencing synthetic metabolic valve silences gene expression of a gene selected from: fabI, gltA, lpd, zwf, and udhA and an additional gene.
13. The multi-stage fermentation bioprocess of claim 10 , wherein the proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme is an enzyme selected from the group: fabI, gltA, ldp, zwf, or udhA.
14. The multi-stage fermentation bioprocess of claim 10 , wherein the proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme selected from: fabI, gltA, lpd, zwf, and udhA and an additional enzyme.
15. The multi-stage fermentation bioprocess of claim 10 , wherein at least one silencing synthetic metabolic valve is characterized by CRISPR interference of gene expression of a gene that is a fabI, gltA, lpd, zwf, or udhA gene and expression of a CASCADE plasmid comprising an array of guide RNA genes.
16. The multi-stage fermentation bioprocess of claim 10 , wherein at least one proteolytic synthetic metabolic valve is characterized by expression of the proteolytic enzyme operably linked to a C-terminal DAS4 peptide tag and controlled proteolysis of a fabI, gltA, ldp, zwf, or udhA enzyme by the synthetic metabolic valve is selective for the tag by clpXP protease upon induction of sspB chaperone protein.
17. The multi-stage fermentation bioprocess of claim 10 , wherein the rate of production of said product during the productive stationary phase is reduced less in response to a change of an environmental condition as compared to a cell lacking the synthetic metabolic valves.